Large Cohort Study Finds Blood NAD Levels Correlate With Cardiovascular Disease Rather Than Aging
A comprehensive analysis of over 1,000 adults reveals that whole-blood NAD levels remain stable or increase with age in healthy individuals, challenging popular longevity narratives. Instead, reduced levels of the coenzyme strongly track with cardiovascular disease and hypertension.
Share this story
For years, the longevity industry has marketed nicotinamide adenine dinucleotide (NAD) as a youth molecule that inevitably drains away as we get older. A major new study published in Nature Metabolism upends that foundational claim, showing that whole-blood NAD levels do not actually drop with chronological age in healthy adults.[1][2]
Instead of tracking the passage of time, the coenzyme appears to act as a biomarker for specific chronic illnesses. Researchers found that lower NAD levels correlate strongly with cardiovascular disease and hypertension, regardless of how old the patient is.[1]
The findings emerge from a cross-sectional analysis conducted by researchers at Vilnius University in Lithuania, alongside biotechnology firms SensoLife and LifeLab1. The team evaluated 1,340 whole-blood NAD measurements taken from 1,068 adults between 2023 and 2025.[2]
"These findings indicate that whole-blood NAD levels track cardiovascular disease rather than chronological age," the study authors wrote in their November 4 publication. The results challenge the widespread assumption that declining NAD is a universal feature of human aging.[1]
NAD is an essential coenzyme found in all living cells, playing a critical role in energy metabolism and cellular repair. While previous animal studies showed age-related declines in tissues like skeletal muscle and skin, human blood data had remained inconsistent until this large-scale cohort clarified the picture.[2]
Healthy Aging vs. Chronic Disease
To isolate the effects of natural aging, the research team focused first on 707 healthy adults who reported no chronic diseases and took no NAD-boosting supplements. In this healthy cohort, whole-blood NAD concentrations remained remarkably stable as participants aged.[2]
The data showed a clear sex difference in baseline levels and aging trajectories. Men maintained a higher median NAD concentration overall at 19.91 micromolar (µM), compared to 17.43 µM in women, and their levels stayed flat across decades.[2]
In healthy women, the researchers actually observed a modest but statistically significant increase in NAD levels as they aged. The study authors noted that this age-associated rise in female participants had not been previously documented in longevity literature.[2]
The pattern shifted dramatically when researchers analyzed the 243 participants living with chronic diseases. In this group, the age-related stability vanished, with men showing a decline over time and women losing the upward trajectory seen in their healthy counterparts.[2]
When breaking down specific conditions, the drop in NAD was heavily concentrated among patients with cardiovascular disease and high blood pressure. Other chronic conditions, such as dyslipidemia, showed no such reduction, suggesting the NAD deficit is disease-specific rather than a general marker of illness.[2]
Implications for the Supplement Market
The longevity supplement market has grown rapidly by selling NAD precursors like nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). These products are heavily marketed as anti-aging interventions designed to correct a presumed universal deficit.[2]
By demonstrating that healthy older adults do not actually lack blood NAD, the Lithuanian study weakens the primary sales argument for these supplements. If there is no general age-related deficit to correct, the preventative value of boosting NAD in healthy individuals becomes questionable.[4]
The study did confirm that supplements successfully raise blood levels. Among the 22 participants who reported taking NAD boosters, concentrations were significantly higher, with 27 percent reaching between 38 and 58 µM—roughly double or triple the normal baseline.[2]
In a small exploratory arm of the research, two volunteers taking 1,000 milligrams of NMN daily saw their NAD levels spike from roughly 19 µM to over 50 µM within days. However, achieving these elevated numbers does not automatically translate to extended lifespan or improved clinical function.[2]
Recent clinical trials have struggled to prove that artificially elevated NAD delivers tangible cardiovascular or cognitive benefits. In older adults with high blood pressure, adding NR to a walking program did not lower systolic pressure any more than exercise alone.[4]
The Tissue vs. Blood Debate
While the Vilnius University findings provide robust data on whole-blood NAD, they do not entirely close the book on age-related cellular decline. The researchers emphasized that their measurements reflect circulating blood levels, which may not mirror what happens inside specific organs.
Previous research has documented NAD depletion in the skeletal muscle, brain tissue, and skin of aging animal models. It remains scientifically plausible that human organs experience localized NAD deficits even while blood concentrations remain perfectly stable.
Measuring tissue-specific NAD in living humans requires invasive biopsies, making large-scale cohort studies nearly impossible to conduct. Whole-blood testing via finger-prick samples offers a practical alternative, but it inherently limits the scope of the conclusions that can be drawn.[2]
The study also leaves the question of causality unanswered. It remains unclear whether low NAD levels actively contribute to the development of cardiovascular disease, or if the disease itself depletes the body's circulating NAD reserves.
"As this research was not designed to investigate causality, these data do not provide direct evidence that NAD supplementation may serve as a treatment for cardiovascular disease or hypertension," the authors cautioned in their report.[1]
Redefining Metabolic Biomarkers
The findings align with a separate Nature Metabolism paper published earlier in 2026 by a team from Amsterdam UMC. That study analyzed seven independent human cohorts and similarly concluded that blood NAD is a poor biomarker for chronological aging.
Together, these large-scale human trials are forcing a pivot in how longevity researchers view metabolic biomarkers. Rather than treating NAD as a ticking biological clock, scientists are increasingly viewing it as a real-time indicator of cardiovascular stress.
When NAD levels drop, the body often experiences increased oxidative stress and inflammation, both of which are primary drivers of hypertension and atherosclerosis. Monitoring these levels could eventually offer clinicians a new tool for assessing cardiovascular risk before severe symptoms emerge.
For the general public, the data suggests that maintaining cardiovascular health naturally preserves NAD levels. The stable concentrations seen in the healthy cohort indicate that the body can maintain its own metabolic currency without pharmaceutical intervention.[2]
For the general public, the data suggests that maintaining cardiovascular health naturally preserves NAD levels.
As research continues to untangle the complex relationship between metabolism and heart disease, the focus is shifting away from reversing age. The most effective way to protect cellular energy may simply be protecting the heart.
Key points
- A study of 1,068 adults found that whole-blood NAD levels do not decline with chronological age in healthy individuals.
- NAD concentrations remained flat in healthy men and showed a modest increase in healthy women as they aged.
- Lower NAD levels were strongly associated with cardiovascular disease and hypertension, regardless of the patient's age.
- The findings challenge the marketing claims of longevity supplements designed to correct a presumed age-related NAD deficit.
What we don’t know
- Whether low NAD levels actively contribute to cardiovascular disease, or if the disease itself depletes the body's NAD reserves.
- If NAD levels in specific human tissues, such as the brain or skeletal muscle, decline with age even when blood levels remain stable.
- Whether artificially boosting NAD levels with supplements can prevent or treat hypertension in patients with cardiovascular disease.
- Clinical Researchers
- Scientists focused on evidence-based medicine who emphasize the new data over previous assumptions.
- Longevity Skeptics
- Medical professionals and analysts who question the efficacy and marketing of anti-aging supplements.
- Metabolic Health Experts
- Physicians who focus on the biochemical mechanisms of aging and disease.
Perspectives this story doesn't cover
- Patients currently taking NAD supplements for anti-aging purposes
- Representatives from companies manufacturing NMN and NR supplements
Sources
[1]Nature MetabolismClinical ResearchersWhole-blood NAD levels track cardiovascular disease but not chronological age
Read on Nature Metabolism →
[2]Managed Healthcare ExecutiveClinical ResearchersLow blood NAD levels track heart disease and hypertension, not aging
Read on Managed Healthcare Executive →
[3]The Lifespan BriefLongevity SkepticsNAD blood levels don't fall with age, study finds, challenging longevity claims
Read on The Lifespan Brief →
[4]AI DiagMeLongevity SkepticsLow NAD Levels Track Heart Disease, Not Aging, Study Finds
Read on AI DiagMe →
More in Health
See all →Cellular Aging
GlyNAC for Biological Aging: How the Dual-Amino Acid Supplement Reverses Cellular Decline
12 sources
Cellular Reprogramming
Cellular Reprogramming Reverses 60 Years of Aging Markers in Human Blood-Derived Neural Cells
5 sources
US Mortality
How a Steep Decline in Unintentional Injuries Drove the 2024 US Life Expectancy Rebound
2 sources
Brown Adipose Tissue
Why Severe Caloric Restriction Triggers Cold Intolerance by Halting Non-Shivering Brown Fat Thermogenesis
5 sources
Comments
Every angle. Every day.
Get Health stories with full source coverage and perspective breakdowns, free every day.




